Compare AMC & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMC | SDGR |
|---|---|---|
| Founded | 1920 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 993.9M | 1.1B |
| IPO Year | 2007 | 2020 |
| Metric | AMC | SDGR |
|---|---|---|
| Price | $2.83 | $15.29 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $2.03 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 49.9M | 860.2K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,848,900,000.00 | $255,869,000.00 |
| Revenue This Year | $11.41 | $0.76 |
| Revenue Next Year | $5.18 | $4.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 4.57 | ★ 23.29 |
| 52 Week Low | $0.93 | $10.95 |
| 52 Week High | $3.26 | $23.02 |
| Indicator | AMC | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 70.16 | 47.85 |
| Support Level | $1.66 | $14.61 |
| Resistance Level | $2.96 | $16.47 |
| Average True Range (ATR) | 0.23 | 0.60 |
| MACD | 0.07 | -0.08 |
| Stochastic Oscillator | 83.71 | 31.94 |
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. The company owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.